Title:
【発明の名称】芳香族スルホニルアルファ-ヒドロキシヒドロキサム酸化合物
Document Type and Number:
Japanese Patent JP2002515900
Kind Code:
A
Abstract:
A sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound that inter alia inhibits matrix metalloprotease activity is disclosed as are a treatment process that comprises administering a contemplated sulfonyl divalent aromatic or heteroaromatic ring hydroxamic acid compound in a MMP enzyme-inhibiting effective amount to a host having a condition associated with pathological matrix metalloprotease activity.
More Like This:
| WO/2001/028548 | TREATMENT OF HEART DISEASE WITH COX-2 INHIBITORS |
| WO/2001/089589 | A NOVEL TREATMENT FOR COUGH |
| WO/2023/185752 | TRIAZOLAMIDE COMPOUND, PREPARATION METHOD THEREFOR, AND USE THEREOF |
Inventors:
Frescos, John, N.
Boheme, Terry, Elle.
Mishku, Brent, Buoy.
Heinz, Robert, M.
McDonald's, Joseph, Jay.
Decresenzo, Gary, A.
Howard, Susan, Sea.
Boheme, Terry, Elle.
Mishku, Brent, Buoy.
Heinz, Robert, M.
McDonald's, Joseph, Jay.
Decresenzo, Gary, A.
Howard, Susan, Sea.
Application Number:
JP53798598A
Publication Date:
May 28, 2002
Filing Date:
March 04, 1998
Export Citation:
Assignee:
Monsanto Company
International Classes:
A61K31/16; A61K31/165; A61K31/166; A61K31/17; A61K31/18; A61K31/198; A61K31/27; A61K31/341; A61K31/351; A61K31/36; A61K31/381; A61K31/382; A61K31/40; A61K31/401; A61K31/4015; A61K31/4025; A61K31/4164; A61K31/4166; A61K31/4184; A61K31/4196; A61K31/42; A61K31/421; A61K31/422; A61K31/423; A61K31/426; A61K31/428; A61K31/44; A61K31/4402; A61K31/4406; A61K31/4409; A61K31/4433; A61K31/4436; A61K31/4439; A61K31/444; A61K31/445; A61K31/4453; A61K31/4465; A61K31/451; A61K31/4525; A61K31/453; A61K31/4535; A61K31/454; A61K31/4545; A61K31/47; A61K31/472; A61K31/495; A61K31/496; A61K31/505; A61K31/506; A61K31/5375; A61K31/5377; A61K31/54; A61K45/00; A61P1/04; A61P1/14; A61P7/02; A61P7/04; A61P7/08; A61P9/00; C07D211/62; A61P9/10; A61P13/12; A61P17/02; A61P19/02; A61P19/08; A61P25/00; A61P25/28; A61P27/02; A61P29/00; A61P35/00; A61P35/04; A61P43/00; C07C317/22; C07C317/44; C07C317/46; C07C317/48; C07C317/50; C07C323/65; C07D207/16; C07D207/404; C07D211/10; C07D211/46; C07D211/52; C07D211/60; C07D211/64; C07D211/96; C07D213/30; C07D213/32; C07D213/34; C07D213/38; C07D213/63; C07D213/64; C07D213/65; C07D213/68; C07D213/70; C07D213/71; C07D213/81; C07D213/82; C07D215/48; C07D217/02; C07D217/26; C07D233/60; C07D233/84; C07D233/90; C07D235/08; C07D239/26; C07D239/28; C07D239/34; C07D239/38; C07D241/12; C07D249/12; C07D263/32; C07D263/46; C07D263/54; C07D263/56; C07D263/58; C07D277/20; C07D277/26; C07D277/36; C07D277/56; C07D277/62; C07D277/66; C07D277/70; C07D277/74; C07D277/76; C07D295/08; C07D295/14; C07D295/15; C07D307/56; C07D307/68; C07D309/08; C07D317/62; C07D317/64; C07D333/18; C07D333/36; C07D333/38; C07D333/40; C07D333/54; C07D335/02; C07D401/04; C07D401/06; C07D401/12; C07D405/04; C07D405/12; C07D409/04; C07D409/12; C07D413/04; C07D413/12; C07D417/12; C07D491/056; C07D491/113; C07D493/10; (IPC1-7): C07C317/46; A61K31/165; A61K31/17; A61K31/18; A61K31/341; A61K31/36; A61K31/381; A61K31/401; A61K31/4164; A61K31/4184; A61K31/4196; A61K31/42; A61K31/421; A61K31/423; A61K31/426; A61K31/428; A61K31/44; A61K31/4436; A61K31/4453; A61K31/47; A61K31/472; A61K31/505; A61K31/5375; A61K31/54; A61K45/00; A61P43/00; C07C323/65; C07D213/30; C07D213/32; C07D213/63; C07D213/70; C07D213/81; C07D213/82; C07D215/48; C07D217/26; C07D233/84; C07D235/08; C07D239/26; C07D239/28; C07D239/34; C07D239/38; C07D241/12; C07D249/12; C07D263/46; C07D263/54; C07D263/58; C07D277/36; C07D277/56; C07D277/62; C07D277/70; C07D295/08; C07D295/14; C07D307/56; C07D317/62; C07D317/64; C07D333/38; C07D409/04; C07D413/04
Attorney, Agent or Firm:
Akira Asamura (3 outside)